Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 2-Week PTSD therapy cut substance use? new trial aims to find out

NCT ID NCT06968832

Symptom relief Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a condensed form of PTSD therapy, called Massed Prolonged Exposure (M-PE), can help people who are also being treated for substance use disorders. About 168 adults will either receive M-PE alongside their usual substance use program or continue with standard care. Researchers will track PTSD symptoms, substance use, and quality of life over six months to see if the fast-track therapy leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Massed Prolonged Exposure Therapy (M-PE)
What this could lead to
If it works, this could provide an effective way to treat PTSD alongside substance use treatment, improving mental health and reducing substance use.
What could go wrong
This is a relatively small trial (168 participants) and compares M-PE to usual care, so results may not apply to all settings. The therapy is intensive and may not be suitable for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 168 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18+ * Enrolled in SUD treatment at Gateway Community Services * Meet DSM-5 criteria for a SUD (Tobacco Use Disorder alone not sufficient for inclusion) * Meet DSM-5 criteria for PTSD * Able to give informed consent Exclusion Criteria: * severe cognitive impairment * current suicidal or homicidal intent requiring immediate treatment * current unstable psychotic or manic symptoms not attributable to SUD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Comorbidity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute stress disorder post-traumatic stress disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Comorbidity Posttraumatic stress disorder (PTSD) Substance use disorders (SUD) Trauma and stressor related disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gateway Community Services

    RECRUITING

    Jacksonville, Florida, 32204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.